未播出

持續追蹤 · 1 篇報導

Novo Nordisk's lawsuit over Eli Lilly GLP-1 ads

首次播出 最新播出

發展中下次查核 ：Further court proceedings or a resolution of the case.

最新進展

Novo Nordisk has sued Eli Lilly in federal court, alleging its direct-to-consumer GLP-1 drug ads make false and misleading dosing comparisons; Lilly says the ads are truthful. No court ruling, settlement or other resolution is reported, so the case remains open.

新聞追蹤第 1 天

1 篇報導11 家媒體11 個來源1 部影片

  • 尚無標註日期的事件
    1. 第 1 次更新Four Drugs, One Courtroom: Novo Nordisk Takes Eli Lilly to Trial Over GLP-1 Ads

    事件至今

    1. 第 1 次更新

      Four Drugs, One Courtroom: Novo Nordisk Takes Eli Lilly to Trial Over GLP-1 Ads

      A New Jersey federal complaint says Lilly's Zepbound and Mounjaro ads stack the dosing deck against Wegovy and Ozempic. The market they share is reshaping the industry.

      本篇報導後仍無定論

      • Any verbatim Lilly on-the-record statement beyond the general "truthful and based on the best available scientific evidence" framing. The source file does not include one.
      • How the court will treat the question of which doses are properly comparable, and which clinical trials it considers current.
      • Whether the case produces a settlement, a ruling on the injunction, or a long discovery fight.

    經過

    1. 開啟1 篇報導

    相關各方

    地點

    • CopenhagenCopenhagen, Denmark1 篇報導
    • IndianapolisIndianapolis, IN, USA1 篇報導
    • US District Court for the District of New Jersey50 Walnut St #4015, Newark, NJ 07102, USA1 篇報導

    我們就此事閱讀過的所有媒體

    11 個來源11 家媒體1 部影片